GlassScriptPhysician profile
Mehrdad Pakdaman
NPI 1942352315
$12,284.95
in general payments reported to CMS, 2019-2025
46 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,771 · 2020: $392 · 2021: $1,312 · 2022: $1,592 · 2023: $1,959 · 2024: $2,895 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,186 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,186.33 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,615.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,676.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Regeneron Healthcare Solutions, INC. | $970.50 | 2023-2025 | Dupixent |
| Abbvie INC. | $937.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $749.95 | 2021-2025 | |
| Ardelyx, INC. | $447.28 | 2023-2025 | Ibsrela |
| Shield Therapeutics INC | $331.48 | 2024-2025 | |
| Genzyme Corporation | $330.71 | 2023-2025 | |
| Pfizer INC. | $314.17 | 2019-2024 | |
| Astellas Pharma US INC | $295.48 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.00 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.91 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Sumitomo Pharma America, INC. | $248.08 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $247.13 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.10 | 2019-2024 | Synjardy, Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehrdad Pakdaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.